PT3603620T - Composição lipossomal e composição farmacêutica - Google Patents

Composição lipossomal e composição farmacêutica

Info

Publication number
PT3603620T
PT3603620T PT187769575T PT18776957T PT3603620T PT 3603620 T PT3603620 T PT 3603620T PT 187769575 T PT187769575 T PT 187769575T PT 18776957 T PT18776957 T PT 18776957T PT 3603620 T PT3603620 T PT 3603620T
Authority
PT
Portugal
Prior art keywords
composition
liposome
pharmaceutical composition
pharmaceutical
liposome composition
Prior art date
Application number
PT187769575T
Other languages
English (en)
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of PT3603620T publication Critical patent/PT3603620T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/02—Ammonia; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT187769575T 2017-03-31 2018-03-30 Composição lipossomal e composição farmacêutica PT3603620T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017069836 2017-03-31

Publications (1)

Publication Number Publication Date
PT3603620T true PT3603620T (pt) 2025-12-02

Family

ID=63676279

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187769575T PT3603620T (pt) 2017-03-31 2018-03-30 Composição lipossomal e composição farmacêutica

Country Status (20)

Country Link
US (3) US11413244B2 (pt)
EP (1) EP3603620B1 (pt)
JP (3) JP6728482B2 (pt)
KR (1) KR102328463B1 (pt)
CN (4) CN114224840A (pt)
AU (1) AU2018246024B2 (pt)
BR (1) BR112019020406B1 (pt)
CA (1) CA3058127C (pt)
DK (1) DK3603620T3 (pt)
ES (1) ES3055110T3 (pt)
FI (1) FI3603620T3 (pt)
HR (1) HRP20251519T1 (pt)
LT (1) LT3603620T (pt)
PL (1) PL3603620T3 (pt)
PT (1) PT3603620T (pt)
RS (1) RS67470B1 (pt)
RU (1) RU2734900C1 (pt)
SI (1) SI3603620T1 (pt)
SM (1) SMT202500440T1 (pt)
WO (1) WO2018181963A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2734900C1 (ru) * 2017-03-31 2020-10-26 Фуджифилм Корпорэйшн Липосомальная композиция и фармацевтическая композиция
JP7036919B2 (ja) * 2018-06-20 2022-03-15 富士フイルム株式会社 薬物を内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬
EP3861987A4 (en) * 2018-10-01 2021-09-15 FUJIFILM Corporation COMBINATION DRUG CONTAINING A LIPOSOME COMPOSITION ENCAPSULATING A DRUG AND A PLATINUM PREPARATION
MX2021006547A (es) * 2018-12-17 2021-08-11 Eisai R&D Man Co Ltd Formulacion que comprende liposomas.
US11154501B2 (en) 2019-08-09 2021-10-26 Nanophase Technologies Corporation Method of enhancing the efficacy and stability of ingredients in suspensions
AR122024A1 (es) * 2020-05-06 2022-08-03 Nanotech Pharma Inc Formulaciones de liposomas para el tratamiento de cánceres y de la resistencia a los medicamentos de los cánceres
CN113876711A (zh) * 2020-07-01 2022-01-04 江苏长泰药业有限公司 一种盐酸阿霉素脂质体的制备工艺
WO2022132781A1 (en) * 2020-12-14 2022-06-23 Nanotech Pharma Inc. Compositions and methods for delivery of anticancer agents with improved therapeutic index
JP6884496B1 (ja) * 2021-03-08 2021-06-09 ユーシービージャパン株式会社 レベチラセタムを有効成分とする注射用製剤
CN113101374B (zh) * 2021-04-08 2022-10-25 陕西科技大学 一种阿拉伯胶-明胶修饰牡丹籽油纳米脂质体及其制备方法
JPWO2022250013A1 (pt) * 2021-05-24 2022-12-01
JPWO2022250015A1 (pt) * 2021-05-24 2022-12-01
MX2024010261A (es) 2022-03-31 2024-08-30 Eisai R&D Man Co Ltd Composición de liposomas y composición farmacéutica que contiene liposomas.
CN120225196A (zh) 2022-11-21 2025-06-27 富士胶片株式会社 含有内含拓扑替康或其盐的脂质体组合物及dna损伤修复抑制剂的组合药物
GB202315012D0 (en) * 2023-09-29 2023-11-15 Univ Bath Composition

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
ATE238039T1 (de) 1998-09-16 2003-05-15 Alza Corp In liposomen eingeschlossene topoisomerase inhibitoren
DE60115044T2 (de) 2000-06-30 2006-08-03 Inex Pharmaceuticals Corp., Burnaby Liposomale antineoplastische arzneimittel und deren verwendungen
US20080075762A1 (en) 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
US20070231379A1 (en) * 2002-08-29 2007-10-04 Slater James L Liposome-entrapped topoisomerase inhibitors
ATE450251T1 (de) * 2004-05-17 2009-12-15 Tekmira Pharmaceuticals Corp Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
JP4990786B2 (ja) 2004-11-05 2012-08-01 イネックス ファーマシューティカルズ コーポレイション 薬物リポソーム製剤を安定化するための組成物および方法
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
US20070088414A1 (en) * 2005-05-25 2007-04-19 Campbell Robert L Particulate formulations for intradermal delivery of biologically active agents
US20080206139A1 (en) * 2006-11-03 2008-08-28 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
CN101485629B (zh) * 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
US20110159080A1 (en) 2008-06-03 2011-06-30 Colin Lowery Composition comprising liposome-entrapped doxorubicin and methods of administration
AR076634A1 (es) * 2008-11-21 2011-06-29 Medgenesis Therapeutix Inc Composiciones y metodo para tratar desordenes del sistema nervioso central
US20100249073A1 (en) 2009-03-27 2010-09-30 Robert Sabin Prophylactic and therapeutic treatment of Alzheimer's disease using phytic acid and phytate to reduce amyloid beta plaque and tau protein
HRP20161157T1 (hr) * 2009-03-30 2016-11-18 Eisai R&D Management Co., Ltd. Liposomski pripravak
US11357728B2 (en) * 2009-10-26 2022-06-14 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt
EP2531175A2 (en) * 2010-02-01 2012-12-12 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Liposomes comprising amphipathic drugs and method for their preparation
EP2630953B1 (en) 2010-12-27 2017-08-09 Terumo Kabushiki Kaisha Liposome composition and process for production thereof
US20140328759A1 (en) * 2011-10-25 2014-11-06 The University Of British Columbia Limit size lipid nanoparticles and related methods
CN102764234A (zh) 2012-08-03 2012-11-07 上海现代药物制剂工程研究中心有限公司 一种盐酸拓扑替康靶向脂质体制剂及其制备方法
AU2013331077A1 (en) * 2012-10-19 2015-04-16 The Regents Of The University Of California Treating tumors of the central nervous system
US20160194625A1 (en) * 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Chimeric polynucleotides
CN104771361B (zh) * 2014-01-14 2018-06-01 中国科学院上海药物研究所 一种盐酸拓扑替康脂质体纳米制剂及其制备方法
US10369104B2 (en) 2014-04-01 2019-08-06 Children's Hospital Los Angeles Targeted polymerized nanoparticles for cancer treatment
JP6316182B2 (ja) * 2014-12-19 2018-04-25 富士フイルム株式会社 リポソームの製造方法及びリポソーム製造装置
WO2017079303A1 (en) 2015-11-02 2017-05-11 The Cleveland Clinic Foundation Sequentially orchestrated immune checkpoint therapy for the treatment and prevention of cancer
JP6602886B2 (ja) 2015-11-02 2019-11-06 富士フイルム株式会社 ゲムシタビンリポソーム組成物を含む腫瘍治療剤およびキット
EP3535026A1 (en) 2016-11-02 2019-09-11 Ipsen Biopharm Limited Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
AU2017372856B9 (en) 2016-12-05 2024-01-04 Pharmacosmos Holding A/S Preservation of immune response during chemotherapy regimens
RU2734900C1 (ru) 2017-03-31 2020-10-26 Фуджифилм Корпорэйшн Липосомальная композиция и фармацевтическая композиция
JP7036919B2 (ja) 2018-06-20 2022-03-15 富士フイルム株式会社 薬物を内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬
EP3861987A4 (en) 2018-10-01 2021-09-15 FUJIFILM Corporation COMBINATION DRUG CONTAINING A LIPOSOME COMPOSITION ENCAPSULATING A DRUG AND A PLATINUM PREPARATION

Also Published As

Publication number Publication date
AU2018246024B2 (en) 2020-08-06
AU2018246024A1 (en) 2019-10-17
ES3055110T3 (en) 2026-02-10
KR102328463B1 (ko) 2021-11-17
WO2018181963A1 (ja) 2018-10-04
BR112019020406A2 (pt) 2020-04-22
DK3603620T3 (da) 2025-12-01
JP7012124B2 (ja) 2022-01-27
JP7278436B2 (ja) 2023-05-19
SI3603620T1 (sl) 2026-01-30
JPWO2018181963A1 (ja) 2020-01-16
KR20190120319A (ko) 2019-10-23
US11446247B2 (en) 2022-09-20
RS67470B1 (sr) 2025-12-31
PL3603620T3 (pl) 2026-02-16
CA3058127C (en) 2022-07-05
SMT202500440T1 (it) 2026-01-12
HRP20251519T1 (hr) 2026-01-02
BR112019020406B1 (pt) 2021-10-26
US20220370352A1 (en) 2022-11-24
JP6728482B2 (ja) 2020-07-22
CN116763733A (zh) 2023-09-19
EP3603620B1 (en) 2025-10-29
JP2020158542A (ja) 2020-10-01
EP3603620A4 (en) 2020-03-25
JP2022043357A (ja) 2022-03-15
FI3603620T3 (fi) 2025-12-02
CN114224840A (zh) 2022-03-25
US20210038518A1 (en) 2021-02-11
RU2734900C1 (ru) 2020-10-26
EP3603620A1 (en) 2020-02-05
LT3603620T (lt) 2025-12-10
US11413244B2 (en) 2022-08-16
CN116763734A (zh) 2023-09-19
CA3058127A1 (en) 2018-10-04
CN110505869A (zh) 2019-11-26
US20200016079A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
SI3603620T1 (sl) Sestava liposomov in farmacevtska sestava
ZA202000439B (en) Liposome compositions comprising weak acid drugs and uses thereof
ZA201802125B (en) Pharmaceutical composition and application thereof
ZA201802003B (en) Dual function proteins and pharmaceutical composition comprising same
IL269061A (en) A pharmaceutical preparation containing Selexifag
IL271986A (en) pharmaceutical preparation
EP3064523A4 (en) Copolycarbonate and composition comprising same
EP3307265A4 (en) Pharmaceutical combination and uses thereof
IL262929B1 (en) Preparations for treatment, methods of their preparation and their uses
GB201712159D0 (en) Pharmaceutical composition
HUE068810T2 (hu) Gyógyászati készítmény
IL272419A (en) Pharmaceutical composition
GB201719447D0 (en) Pharmaceutical composition
PL3658122T3 (pl) Kompozycja farmaceutyczna zawierająca sakubitryl i walsartan
IL260321B (en) A multi-antigenic structure and a pharmaceutical preparation containing it
PT3302483T (pt) Composições farmacêuticas e seu uso
IL257621B (en) A catechol derivative and a pharmaceutical preparation that includes it
GB201519644D0 (en) Therapy and pharmaceutical composition
EP3395370A4 (en) Liposome and liposome composition
ZA201903341B (en) Pharmaceutical compositions and uses thereof
GB201713920D0 (en) Pharmaceutical compositions and uses thereof
GB201718320D0 (en) Therapeutic substances and their preparation
GB201708329D0 (en) Pharmaceutical composition
GB201708328D0 (en) Pharmaceutical composition
GB201705661D0 (en) Pharmaceutical composition